Article
Medicine, General & Internal
Yuxiang Sun, Xiangcang Ye, Hilda Kennedy, Alexander G. A. Smith, Roy G. Smith
Summary: This study investigated the binding and functional characteristics of GHS-R to ligands MK-0677, GHS-25, and ghrelin. It found that synthetic agonists MK-0677 and GHS-25 have higher GH secretagogue activity than ghrelin. The study also identified the C-terminal region, particularly TM6, as critical for ligand-dependent activity in GHS-R. Furthermore, amino acid residues D99 and W276 were found to be essential for ligand binding. These findings advance the understanding of GHS-R structure and function and have implications for future therapeutic applications.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
(2022)
Review
Nutrition & Dietetics
Zheng-Tong Jiao, Qi Luo
Summary: Ghrelin is an endogenous brain-gut peptide secreted in large quantities in humans and rodents, playing a role in appetite regulation and other physiological processes. While research on its effects and regulatory mechanisms has been extensive, its impacts on obesity, disease treatment, etc. have not been fully summarized.
Review
Biochemistry & Molecular Biology
Chihiro Yamada
Summary: GHS-R1a, a key GPCR, is involved in various physiological actions with its ligand ghrelin; dysregulation of GHS-R1a is associated with reduced feeding in various diseases; research on gender differences and stress effects in the physiological actions of ghrelin is still limited.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Geriatrics & Gerontology
Megan Herodes, Lindsey J. J. Anderson, Samuel Shober, Ellen A. A. Schur, Solomon A. A. Graf, Nicola Ammer, Ramiro Salas, Marco Marcelli, Jose M. M. Garcia
Summary: This pilot study evaluated the safety and efficacy of using macimorelin, a growth hormone secretagogue, in cancer cachexia patients. The results showed that one-week administration of macimorelin improved body weight and quality of life in these patients. The importance of this study lies in providing a potential new approach for treating cancer cachexia.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Immunology
Aisa Bahar, Majid MirmohammadKhani, Reza Dabiri, Vahid Semnani, Abbas Pakdel
Summary: The study revealed significantly lower serum ghrelin and mRNA expression in patients with H. pylori infection and gastritis, while GHSR1b expression was significantly higher in this group. Thus, ghrelin axis intermediaries, such as GHSR1b, may serve as potential clinical targets for gastric disorders.
MICROBIAL PATHOGENESIS
(2021)
Review
Oncology
Irene Alexandra Spiridon, Delia Gabriela Apostol Ciobanu, Simona Eliza Giusca, Irina Draga Caruntu
Summary: Ghrelin, an orexigenic hormone, has been implicated in gastrointestinal tract malignancies, but its exact role in cancer metastasis, invasion, and progression remains uncertain. Studies have shown inconsistent results in immunohistochemical expression and serum levels analysis, limiting its clinical significance in cancer outcome prediction.
MOLECULAR MEDICINE REPORTS
(2021)
Article
Endocrinology & Metabolism
Alexandra Labarthe, Philippe Zizzari, Oriane Fiquet, Nicolas Lebrun, Johannes D. Veldhuis, Ferdinand Roelfsema, Christophe Chauveau, Mohammad Bohlooly-Y, Jacques Epelbaum, Virginie Tolle
Summary: The study reveals a sex-dependent dimorphic effect of GHS-R1a signaling on pulsatile GH secretion and meal pattern in mice, with different compensatory mechanisms occurring in the hypothalamus of adult males and females after GHS-R1a deletion. Altogether, the results demonstrate that GHS-R1a signaling plays a more critical role in regulating pulsatile GH secretion during adolescence in males and adulthood in females.
NEUROENDOCRINOLOGY
(2022)
Article
Medicine, Research & Experimental
Jing Tian, Lan Guo, Tienju Wang, Kun Jia, Russell H. Swerdlow, Jeffrey M. Zigman, Heng Du
Summary: Studies have found that cognitive decline is often reported in elderly individuals, and hippocampal function declines with age. The plasma levels of LEAP2 and ghrelin were found to change in cognitively normal individuals older than 60. Experiments with aged mice showed that restoring the balance of LEAP2 and ghrelin improved cognitive performance and mitigated age-related hippocampal deficiencies. Therefore, the LEAP2/ghrelin molar ratio may serve as a biomarker for age-related cognitive decline.
Article
Fisheries
Leandro Rodriguez-Viera, Ignacio Marti, Rebeca Martinez, Erick Perera, Mario Pablo Estrada, Juan Miguel Mancera, Juan Antonio Martos-Sitcha
Summary: The use of additives in aquafeeds has been shown to improve productive indicators in farmed fish. Adding GHRP-6 peptide to the diet of gilthead sea bream resulted in increased growth performance and feed efficiency, with differences observed at different inclusion levels. Further research is needed to better understand the dose-specific effects of this peptide.
Review
Biochemistry & Molecular Biology
Yuan Liang, Wenzhen Yin, Yue Yin, Weizhen Zhang
Summary: Ghrelin-GHSR signaling plays a critical role in energy homeostasis, and therapeutic strategies targeting this system for metabolic disorders involve various approaches such as neutralization of ghrelin, antagonism of ghrelin receptor, and inhibition of ghrelin O-acyltransferase. Compounds targeting this system have shown promising efficacy in animals and in vitro studies, but further clinical trials are needed to validate their efficacy in humans.
CURRENT MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Fumika Karaki, Tomoya Oki, Yuma Sakao, Noriko Sato, Shigeto Hirayama, Kanako Miyano, Yasuhito Uezono, Hideaki Fujii
Summary: This study investigated the function of Ghrelin and its regulatory mechanism on the GHSR receptor, and identified a potential beta-arrestin-biased superagonist through different screening assays. The compound's activity was found to be partially mediated by allosteric binding based on its resistance to a competitive antagonist.
Article
Neurosciences
Jing-Wei Xing, Xin-Yun Tian, Man-Man Chen, Xiu-Hua Peng, Pengfei Gao
Summary: The study investigated the possible material basis of postpartum depression and provided potential novel antidepressant therapy using a mouse model. The results showed that immobilization stress mice exhibited stress activity, low body weight, and reduced feeding status, with increased ghrelin expression in blood.
Review
Biotechnology & Applied Microbiology
Yiding Chen, Xuke Han, Lan Wang, Qing Wen, Liufu Li, Lisha Sun, Qiu Chen
Summary: This article analyzes literature on breast cancer, providing a reference for future research on mechanisms and treatment improvements. The ghrelin system may have an impact on breast cancer treatment methods and prognostic indicators.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
(2022)
Article
Biochemistry & Molecular Biology
Ji Yeon Noh, Chia-Shan Wu, Jennifer A. A. DeLuca, Sridevi Devaraj, Arul Jayaraman, Robert C. Alaniz, Xiao-Di Tan, Clinton D. Allred, Yuxiang Sun
Summary: Chronic low-grade inflammation, known as inflamm-aging, contributes to age-associated diseases. The gut hormone ghrelin and its receptor GHS-R play a role in energy metabolism and inflammation during aging. The gut microbiome also has a critical role in intestinal immunity. GHS-R regulates microbiome homeostasis and gut inflammation during aging.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Jong Han Lee, Bingzhong Xue, Zheng Chen, Yuxiang Sun
Summary: This study demonstrates that GHS-R regulates energy homeostasis by altering feeding patterns, and differentially modulates feeding patterns in a site- and diet-dependent manner.
Article
Radiology, Nuclear Medicine & Medical Imaging
Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Ryo Yano, Kana Hirooka, Makoto Morita, Yusuke Imai, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
Summary: Deep attenuation transducers (DAX) are a feasible and reliable method for liver stiffness measurement, especially for obese patients. Compared to conventional probes and other elastography methods, DAX can successfully measure liver stiffness at various skin-to-liver capsular distances.
JOURNAL OF MEDICAL ULTRASONICS
(2023)
Article
Oncology
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Tomomitsu Matono, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Summary: This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). The study analyzed 485 HCC patients treated with Atez/Bev. The results showed that a PNI >= 47 was significantly associated with improved overall and progression-free survival in these patients.
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Article
Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomomitsu Matono, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Summary: This study aimed to compare the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) as either first- or later-line systemic therapy. The results showed that the median progression-free survival time was 7.7 months in the first-line group and 6.2 months in the later-line group. Hypertension of any grade was more common in the first-line group. The analysis adjusted by inverse probability weighting revealed that the later-line group was significantly associated with progression-free survival.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Guillen Nieto Gerardo, Yoichi Hiasa
Summary: This study conducted a clinical trial on a therapeutic vaccine for chronic hepatitis B (CHB) patients. The vaccine showed excellent safety and antiviral potential 5 years after treatment, reducing viral load and protecting the liver. The results of the study demonstrate long-term efficacy of the vaccine for CHB patients.
FRONTIERS IN MEDICINE
(2023)
Article
Urology & Nephrology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Kana Shiraishi, Yu Hashimoto, Kazuhiro Tange, Shogo Kitahata, Tomoyuki Ninomiya, Sen Yagi, Masakazu Hanayama, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Hideomi Tomida, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: This study aimed to investigate the association between serum albumin levels and erectile dysfunction (ED) in Japanese patients with ulcerative colitis (UC). The results showed an independent inverse association between serum albumin and severe ED in these patients.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Gastroenterology & Hepatology
Fujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada
Summary: The study found that Atez/Bev may be a viable treatment option for uHCC patients with EGV, as long as appropriate endoscopic treatment is carried out. Despite differences in certain liver function parameters between EGV and non-EGV groups, there was no significant variance in progression-free survival rates.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Akio Ido, Hidekatsu Kuroda, Daiki Miki, Masayuki Kurosaki, Yoichi Hiasa, Ryotaro Sakamori, Norifumi Kawada, Taro Yamashita, Goki Suda, Hiroshi Yatsuhashi, Hitoshi Yoshiji, Naoya Kato, Taro Takami, Kazuhiko Nakao, Kentaro Matsuura, Yasuhiro Asahina, Yoshito Itoh, Ryosuke Tateishi, Yasunari Nakamoto, Eiji Kakazu, Shuji Terai, Masahito Shimizu, Yoshiyuki Ueno, Norio Akuta, Masanori Miyazaki, Yasutoshi Nozaki, Masayuki Kabayama, Satoshi Sobue, Akihiro Moriuchi, Tomokatsu Miyaki, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Summary: This study aims to analyze the prognosis of decompensated cirrhotic patients with HCV infection receiving DAA treatment and explore the stratification effect of liver function on prognosis.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomomitsu Matono, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo
Summary: This study compared the outcomes of patients with intermediate-stage hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic therapy. The results showed that Atezo/Bev group had longer median progression-free survival (PFS) compared to LEN group, and Atezo/Bev group demonstrated better efficacy in patients with HCC beyond the up-to-seven criteria.
LIVER INTERNATIONAL
(2023)
Article
Oncology
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada
Summary: This study aimed to evaluate the ability of a TM score involving AFP, AFP-L3, and DCP to predict the prognosis and therapeutic efficacy in HCC patients treated with Atez/Bev. The results showed that the TM score was useful in predicting the overall survival (OS) and progression-free survival (PFS) in these patients. The mALBI grade was also a good predictor of OS and PFS.
Article
Oncology
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Solda, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Valentina Burgio, Fabio Piscaglia, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Summary: The study analyzed the clinical and laboratory characteristics of HCC patients treated with AB and identified potential prognostic factors. A composite score based on these factors showed higher sensitivity and specificity compared to individual variables. The score was validated in a lenvatinib-treated HCC population and showed that AB was more effective in high score patients. This study suggests that the score could help guide therapeutic choice between lenvatinib and AB.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Summary: This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on liver function in patients with hepatocellular carcinoma. The results showed that there was no significant difference in the trend of liver function deterioration between the Atez/Bev and LEN groups. However, caution should be exercised for LEN-treated patients with BCLC advanced stage or those receiving the full dose of LEN.
Article
Geriatrics & Gerontology
Sen Yagi, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Kana Shiraishi, Kazuhiro Tange, Yu Hashimoto, Shogo Kitahata, Tomoyuki Ninomiya, Masakazu Hanayama, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Hideomi Tomida, Yasunori Yamamoto, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: This study suggests that age is independently and positively associated with the prevalence of constipation in patients with ulcerative colitis (UC), with patients over 70 years old having a higher risk of constipation.
GERONTOLOGY AND GERIATRIC MEDICINE
(2023)
Article
Oncology
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hiroshi Shibata, Tomoko Aoki, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Summary: This retrospective study found no significant differences in terms of progression-free survival (PFS) or overall survival (OS) between CP-B patients treated with Atez/Bev or LEN as initial systemic treatment for uHCC.